3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow 3mg AZ-010: new trials by email Literature Review of 3mg AZ-010 trials Research Report on 3mg AZ-010
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome 3mg AZ-010, 1mg AZ010, Staccato Placebo - Cyclic Vomiting Syndrome | Phase 2 | Completed | Alexza Pharmaceuticals, Inc. | 150 | 2021-02-05 | 2025-06-11 |
| Staccato® Granisetron Multiple Dose PK 0.5mg AZ-010, 1mg AZ-010, 3mg AZ-010 - Healthy | Phase 1 | Completed | Alexza Pharmaceuticals, Inc. | 30 | 2020-03-10 | 2020-10-30 |
| Staccato® Granisetron Single Dose PK 0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010 - Healthy | Phase 1 | Completed | Nova Pneuma Inc. | 36 | 2019-11-04 | 2026-04-13 |
Abdominal Pain (1) · Familial cyclic vomiting syndrome (1) · Foodborne Diseases (1) · Migraine Disorders (1) · Nausea (1) · Vomiting (1)
Alexza Pharmaceuticals, Inc. (2) · Nova Pneuma Inc. (1)
United States (3)
Larry Carter, PhD (1) · Phillip Mathew, MD (1) · Terry O'Reilly, MD (1)